Skip to main content
. 2020 Jun;21(6):1679–1687. doi: 10.31557/APJCP.2020.21.6.1679

Figure 3.

Figure 3

5-Years Survival Rates for (A) Overall (B) Disease-free (C) Locoregional relapse-free between p16-positive and p16-negative in all HNSCC patients, and 5-years OS between p16-positive and p16-negative in (D) non-oropharyngeal subgroup (E) oropharyngeal subgroup, and (F) 5-years OS of the combination between p16 status and smoking status